Is education a risk factor for Parkinson's disease?: A systematic review and meta-analysis

Laurenz Lammer[1,2] MD (ORCID: 0000-0001-5612-4924), Chris Patrick Pflanz[2,5] PhD (ORCID: 0000-0003-2133-0255), Megan Kirk[3,4] PhD (0000-0002-2069-2177, Ammar Shahabuddin[2] (ORCID: 0009-0002-6898-4213), Sarah Bauermeister[2] PhD (ORCID: 0000-0001-9463-6971)

1 Max Planck Institute for Human Cognitive and Brain Sciences, Department of Neurology, Stephanstraße 1a, 04103 Leipzig, Germany

2 Dementias Platform UK, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, United Kingdom

3 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, United Kingdom

4 NIHR Oxford Health Biomedical Research Centre, Warneford Hospital, Oxford OX3 7JX, United Kingdom

5 Oxford Precision Psychiatry Lab, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX3 7JX, United Kingdom

Corresponding author

Laurenz Lammer
lammer@cbs.mpg.de
+49 172 828 7713
Stephanstraße 1a, 04103 Leipzig, Germany

Word count

4985

Running title

SR and MA of education and the risk of PD

Funding and sponsors

The Medical Research Council supports DPUK through Grant MR/T0333771. SB and CPP are supported by DPUK. LL is funded by a scholarship of the German Academic Scholarship Foundation. The funders have not had any influence on this study. The Department of Psychiatry (University of Oxford, Medical Divisions) was the sponsor of this research work, meaning that it has overall control of the data.

Conflicts of interest

The authors declare no conflicts of interest. A reflexivity section of the guarantor (LL) of the study is added in the appendix.

Abstract

Parkinson's disease (PD), a prevalent neurodegenerative disease, has shown a twofold increase in global prevalence over the past 25 years, making research into its causes pivotal. Curiously, higher educational attainment has often been linked to a higher risk of PD. Yet, to our knowledge, these findings have not been validated in a systematic literature review and meta-analysis. Thus, we aimed to evaluate the cumulative evidence for such a link and explore potential sources of heterogeneity in effect size estimates.

We systematically searched PubMed, Psychinfo, Web of Science and Embase and performed extensive citation and similar article searches. Eligible studies included reports of non-interventional quantitative studies that assessed the association between formal education and the risk of idiopathic PD in human adults. Furthermore, we included studies that evaluated the association between educational level and PD symptom severity as a predefined secondary outcome. For the primary outcome, we performed a random-effects meta-analysis to synthesise the effect of education on PD risk. The secondary outcome was synthesised qualitatively. We conducted multiple a priori subgroup analyses to investigate potential causes of heterogeneity. Risk of bias of included studies was assessed using the QUIPS tool. This study was prospectively registered on PROSPERO, (ID: CRD420250651033).

Of 23,648 identified reports, 36 papers met inclusion criteria. The majority of these studies were assessed as having moderate or high overall risk of bias. Meta-analytic findings yielded a non-significant association between formal educational attainment and risk of PD, with a pooled odds ratio (OR) of 1.09 (k = 24; 95% CI: 0.92 – 1.28). Sensitivity analyses excluding outliers yielded similar results. Subgroup analyses did not explain observed heterogeneity in the results. There was no evidence of small study effects or p-hacking. Education appeared to be associated with reduced PD symptom severity but the number and quality of studies was limited. Education is unlikely to be an independent risk factor for PD. Study heterogeneity and methodological limitations preclude firm conclusions, though. Future research should investigate if healthcare access or literacy underly any associations of education and PD. The most plausible explanation for the apparent link between the two is lacking control for multiple comparisons and a distorted discussion of the results of analyses.

Funding was provided by the UK Medical Research Council and the German Academic Scholarship Foundation.

Introduction

PD is the second most common neurodegenerative disease[1] and affects around 12 million individuals globally[2]. Its incidence has surged over the past decades, far exceeding an increase explainable by demographic changes alone[3]. To date, no disease-modifying treatment for PD has been found[4,5] and only around one third of cases can be attributed to mono- and polygenetic causes[6].

Henceforth, it is a paramount aim of PD research to identify and understand the non-genetic causes of disease to facilitate the discovery of preventive interventions[6]. Yet, research on risk factors for the disease has not yielded any actionable results beyond recommendations of increased physical activity[7]. Instead, findings have repeatedly puzzled investigators. Systematic reviews and meta-analyses concerning smoking and alcohol consumption, behaviors almost invariably linked to worse health outcomes, identified them to be associated with lower risk of PD[7,8].

Curiously, multiple studies also linked less education to a lower risk of PD[9–12] which was corroborated by a recent mendelian randomization study[13]. Amongst neurological disorders, PD seems to be a unique case whose age-standardized prevalence increases with a higher regional socio-demographic index[3,14]. However, some studies failed to replicate the association of PD and education[15,16] or had inconsistent [17] or contradictory results[18].

To our best knowledge, no systematic review and meta-analysis has been conducted to investigate the association between education and PD risk. Hence, the evidence level is unsatisfactory. Therefore, the purpose of this systematic review was to critically assess the cumulative evidence regarding the association between formal educational attainment and the risk of PD. Specifically, we aimed to determine whether reported significant findings reflected an empirical relationship or were more likely to be spurious. To this end, we performed a comprehensive and systematic search for relevant studies and conducted a random-effects meta-analysis to quantitatively synthesize effect estimates. Additionally, we qualitatively synthesized the available evidence on the effect of educational attainment on PD symptom burden.

Furthermore, we also aimed to better understand the mechanism of action of the purported association. We hypothesized that the observed correlations actually stem from better access to medical care amongst highly educated people. Additionally, positive associations might be mediated by the negative correlations of education with smoking and the inverse link of smoking and the risk of PD. Therefore, we explored these hypotheses by adding multiple pre-specified subgroup analyses to our meta-analysis.

Methods

Protocols

This manuscript conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[19]. We registered this study with the International Prospective Register of Systematic Reviews (PROSPERO), number CRD420250651033. We amended the protocol of the registration to include a pre-specification of a meta-analysis. We had decided to perform a systematic quantitative analysis and discuss and explore the heterogeneity of our data rather than to leave the door open to unsystematic quantitative approaches such as vote counting[20].

Software and code

We used Rayyan[21] and SRDR+[22] for screening and data extraction, respectively. All calculations were performed in R (Version 4.4.3) and all code can be found on https://github.com/LaurenzLammer/pd_education_ma. The extracted data have been uploaded to the osf (https://osf.io/j9hp2). The analysis script on github is directly linked to the dataset in the osf repository so that all analyses and figures can be reproduced easily. Additionally, it produces many more plots and tables on our sensitivity analyses that did not make it into the appendix. Moreover, the scripts can be downloaded and modified to allow the exploration of the effects of changing assumptions made in our calculations (e.g. the correlation when aggregating effect sizes).

Study selection

Population

We included studies of human adults (>= 18a) that had at least 20% of participants above the age of 50 years due to PD's age dependence. We considered original research studies of individual participants such as cohort studies, cross-sectional studies, case-control studies and studies using instrumental variable methods (e.g. Mendelian Randomization) as well as studies investigating predictors of symptom severity in clinical samples but excluded all other forms of studies (e.g. qualitative studies, case reports, ecological studies or intervention studies).

Exposure

We only included studies that investigated education as a predictor of interest. Studies that merely assessed education as descriptive statistic or a control variable were not included.

Outcome

Our primary outcome was the risk of idiopathic PD. Studies were included independent of whether they measured this as an odds ratio (OR), risk ratio (RR), hazard ratio (HR) or otherwise. Studies on atypical parkinsonian syndromes (e.g. multiple system atrophy) did not meet our inclusion criteria. Our secondary outcome was the severity of PD's core

symptoms (tremor, rigor, akinesia/bradykinesia, postural instability). Reports had to be either in English or German to be included in the review to enable dual screening and dual data extraction.

Search strategies

Fig. 1 provides an overview of our search and selection strategy. We searched PubMed and Web of Science (WoS) directly, and PsychInfo and Embase independently via Ovid for relevant records using a combination of relevant keywords and controlled vocabulary without restrictions on publication date. Our search strategy was developed based on previous work on aetiological search filters[23]. We piloted the Pubmed search strategy using a set of nine studies identified in an unsystematic literature search and performed a peer review of electronic search strategies (PRESS) for all strategies[24]. The appendix contains full search terms and dates of the database searches. Additionally, we iteratively performed backward citation searching (WoS), forward citation searching (both WoS and Scopus) and similar articles searching (PubMed) on all records included after full-text screening in April 2025. MK & LL manually deduplicated potential duplicates identified by Rayyan. The PRISMA flowchart[19] in Fig. 2 provides information on the number of records identified by the different components of the search strategy.

Figure 1: Overview of the search and screening strategies.

Screening

MK and LL independently performed title and abstract screening on 50% of the records identified in the database searches after deduplication while being masked to each other's decisions. LL screened the remaining records. In case of uncertainty or

disagreements, the screeners discussed the records in question until they reached a consensus.

MK, PP and LL did the independent and masked full-text screening of all remaining records. Each record was screened by at least two reviewers (LL screened all). Consensus on inclusion / exclusion in case of doubt or disagreement was reached by a discussion in the team.

Retractions and errata

We searched for retractions or corrections of reports selected after full text screening using the retraction watch database on April 24th 2025.

Data extraction

We designed a data extraction form in SRDR+ based on the Cochrane Handbook [25], which two review authors (AS and LL) used to independently extract data from eligible studies. We compared the extractions using SRDR+'s comparison tool and resolved any discrepancies through discussion. Please refer to the appendix for a list of extracted information.

After consolidating the extractions, we manually adapted the data exported from SRDR+ to align them with the format required for meta-analysis in R.

Risk of bias assessment

For every included study the risk of bias (RoB) was determined using the revised QUIPS tool[26] by the two extractors independently. Assessors were not masked to any aspects of the reports when making RoB assessments[27] but to each other's judgements. Any conflicts were resolved through discussion between the two. For the assessment of the overall RoB of a study, the worst score across the most important QUIPS domains (education measurement, PD measurement, confounding, analysis and reporting) was decisive. We created a traffic light RoB plot for the primary and secondary outcome using the rob_traffic_light function from **{robvis}**. Additionally, we created weighted domain-summary RoB plots using the rob_summary function of **{robvis}** to illustrate overall RoB per domain. For the secondary outcome, we created an unweighted plot.

Linking multiple reports of the same studies

If multiple reports based on the same studies were identified, we prespecified to choose the report with the lowest RoB according to the QUIPS tool for quantitative synthesis.

Data synthesis

We categorized the identified studies depending on whether they investigated our primary (risk of PD) or secondary outcome (severity of core PD symptoms). Data were considered suitable for pooling if participants' risk of PD was investigated in relation to their level of formal education.

Prior to analysis, we log-transformed ORs. To obtain a log-transformed standard error for each effect, we applied the SE.SMD_from_OR.CI function from **{metaHelper}** to the upper and lower limits of the OR confidence interval and multiplied the result by $\frac{\pi}{\sqrt{3}}$ *(Chinn, 2000)*.

As education across time and space as well as the study designs are highly heterogenous, we calculated a random-effects model to pool effect sizes. We employed the metagen function of **{meta}** and used the Paule-Mandel procedure [29] to calculate the heterogeneity variance τ^2 and the Knapp-Hartung adjustment [30] to calculate the confidence interval around the pooled effect.

Assessment of heterogeneity and subgroup analyses

We tested the statistical heterogeneity with the Chi^2 test of Cochran's Q at a significance level of 0.05 and the I^2 statistic as returned by the metagen function. I^2 values of 25%, 50% and 75% were considered indications of low, moderate and substantial heterogeneity, respectively[31].

We prespecified that we would investigate outliers and influential cases if I^2 exceeded 50%. As a sensitivity analysis, we ran the find.outliers function from **{dmetar}** to identify studies whose effect sizes do not overlap with the pooled effect's confidence interval and recalculated our analysis excluding these studies. To investigate influential cases, we employed the InfluenceAnalysis function from **{dmetar}**.

In our registration, we prespecified three study characteristics for subgroup analyses to explain between-study heterogeneity. As education is negatively correlated with smoking and smoking is negatively correlated with the risk of Parkinson's disease[7], we conducted a subgroup analysis to test whether controlling for smoking or not contributed to the heterogeneity. To this end, we updated the metagen meta-analysis setting the argument "subgroup" to the variable distinguishing studies by this characteristic.

Furthermore, we distinguished studies that assessed the general population and those that did not (e.g. inpatient samples) and tested if this explains some of the heterogeneity. Likewise, we differentiated studies that clinically examined all participants and those that did not and investigated this classification's effect on heterogeneity. Moreover, we explored if effects differ between high- and, low- and middle-income countries by calculating another subgroup analysis. Please see the appendix for details on the categorization.

Sensitivity analysis

We conducted sensitivity analyses calculating meta-analsyses only including a) studies that reported ORs (no RRs, HRs, etc.), b) no outliers as identified by find.outliers, c) no studies deemed to have an overall high RoB, d) no mendelian randomization studies, e) only the Swedish register-based study with the lowest RoB.

Assessing small study effects, publication bias and p-hacking

As recommended by Harrer et al.[32] we applied a set of methods to investigate publication bias, small study effects and p-hacking. We provide a standard funnel plot produced by the funnel function from **{meta}** to allow for a visual examination of small study effects. We had prespecified that we would perform all following methods on a subset of studies after the exclusion of outliers detected by find.outliers if I^2 exceeds 75%.

We performed Rücker's limit meta-analysis method using the limitmeta function from **{metasens}** and produced the adapted funnel plot using the funnel.limitmeta function. Additionally, we performed a p-curve analysis using the pcurve function of **{dmetar}**. Furthermore, we used the pcurve function to calculate a corrected effect size by providing a sample size for every study.

Effect measures

Most of the studies used ORs as effect measures. If adjusted and unadjusted ORs were reported, we used the adjusted ones. We treated RRs as ORs if the sample was population based and hence the base rate of PD was low. There is no clear guidance on how to handle HRs or more infrequent outcome measures like standardized incidence ratios [20,33]. For the sake of completeness, we treated them as ORs, too but ran a sensitivity analysis only including studies reporting ORs. We handled ORs from mendelian randomization studies analogously.

We aligned the direction of effects so that higher ORs indicate higher odds amongst more educated individuals. We adapted reported effect sizes from reports that did not base their estimates on a group comparison but e.g. years of schooling to homogenize them with the others. If reports included effect estimates for multiple comparisons (e.g. illiterates vs others and <5 years of schooling vs others) or Mendelian Randomization studies provided effect size estimates based on various calculation methods, we aggregated the estimates using the aggregate function of **{metafor}** setting ρ (the correlation of the sampling errors) to 0.6. In two cases we calculated an OR using oddsratio() from **{epitools}** based on raw count data. If an OR was reported without a standard error (SE), or no OR but beta-coefficients and SEs from logistic regression were reported, we used standard formulae to calculate the effect size with its confidence interval. Please see the appendix for details on all these procedures.

Certainty of evidence assessment

We applied the GRADE approach to certainty of evidence assessment[34,35]. All factors determining the certainty of evidence were evaluated according to the GRADE handbook[36]. However, as suggested by Morgan et al. and Foroutan et al., we did not downgrade observational evidence on principle as the best evidence for our research question is from observational studies[37,38]. We did not translate QUIPS categories to

GRADE categories but followed the advice of the GRADE handbook and attempted to judiciously consider the contribution of each study to the overall results[36]. The included studies did not allow us to discern a baseline risk of Parkinson's disease from the body of evidence. Hence, we relied on the analysis of Elbaz et al. that calculated a lifetime risk of 1.65%[39] as an approximation. It should be noted that other analyses produced substantially higher estimates, though[40]. We calculated the absolute risk as $p_{high\ education}$ = (OR * $p_{baseline}$) / (1 − $p_{baseline}$ + OR * $p_{baseline}$)[41] and derived upper and lower limits analogously.

Results

Study selection

We identified 15,801 records across the four databases. After deduplication, we screened 11,121 records, from which we reviewed 67 full-text documents, and finally included 29 papers. Citation and similar articles searches yielded an additional 7,847 records of which 10 were chosen for full-text screening and 7 were ultimately included in our analysis, resulting in a total number of 36 reports included after full-text screening. At title and abstract screening, the agreement was 99.39% and Cohen's kappa 51.77% because of the high chance of random agreement to exclude. At full-text screening, the agreement between the three raters was 90.3 % and 90.2% and Cohen's kappas were 80.5% and 80.5%. Fig. 2 provides details on the screening process. A table on characteristics of excluded studies[42–50] with initial disagreement or uncertainty at full-text screening is provided in the appendix (Table S1)[51]. None of our records were identified in the Retraction Watch database.

Figure 2: Flowchart delineating the search and screening process according to the 2020 PRISMA statement. Education no poi = Education was not investigated as a predictor of interest.

Description of studies

Characteristics and results of individual studies

The identified studies employed a broad range of approaches to investigate the link between education and the risk of PD. Multiple studies on our primary outcome used data from pre-existing epidemiological studies like the UK Biobank (n = 10, 36%), five studies were based on large health registers from Scandinavia or China (18%) and others purposively sampled participants for classic case-control designs (n = 9, 32%). Mendelian randomization studies based their estimates on large GWAS (n = 4, 14%). All studies on our secondary outcome used patient samples. The different study designs went hand-in-hand with divergent approaches to the assessment of PD. Only a minority of reports on our primary outcome assessed all participants based on established diagnostic criteria (n = 9, 32%). The operationalization of education was highly heterogenous, too. Across both outcomes, seven studies assessed it continuously (19%), while others used a dichotomous (n = 9, 36%) or polytomous categorization (n = 20, 56%) with diverse cut-offs. Moreover, while ORs (n = 21, 75%) were the most prevalent type of effect estimate for our primary outcome, five reports calculated HRs (18%) or yet other effect measures (n = 2, 7%). Furthermore, while most studies controlled for the effects of age and gender (n = 26, 72%), the additionally included confounders were highly heterogenous between studies. Several studies were conducted in low- or middle-income countries (n = 10, 28%) but the majority of reports were from high-income countries (n = 26, 72%). We excluded one of the 36 reports from further analysis due to redundance[52]. We found 27 reports investigating our primary

outcome[11,12,15–17,53–74] and 7 for our secondary outcome[49,75–81]. One study using the age at symptom onset[80] as its outcome did not fit in either group exactly and we grouped it with the studies on our secondary outcome. Table 1 provides an overview of the reports on our primary outcome included in our review. The similar table S2 contains information on reports on our secondary outcome.

Characteristics of the included studies for the primary outcome

Report	Study design	Location	Sample size	Diagnostic criteria	Representative sample	All participants examined	Controlled for smoking	Income category	Effect measure	Effect
Achbani 2022	case-control	Morocco	540		no	no	no	LMIC	OR	none vs university: 0.5 (0.21 - 1.02); primary vs university: 0.51 (0.23 - 1.1); secondary vs university: 0.56 (0.25 - 1.28)
Baldereschi 2003	cross-sectional	Italy	4,496	study specific	yes	yes	yes	HIC	OR	per year: 0.86 (0.66 - 1.1)
Chen 2015	longitudinal	China	74,941		yes	no	no	LMIC	OR	=< primary vs < high school: 1.3 (0.7 - 2.4); =< primary vs >= high school: 1.6 (1 - 2.7)
Fardell 2020	case-control	Sweden	1,189,134	ICD	yes	no	no	HIC	HR	no highschool vs highschool: 1.2 (1.01 - 1.32); no highschool vs university: 1.37 (1.19 - 1.58)
Frigerio 2005	case-control	USA	392	study specific	yes	yes	no	HIC	OR	=<9 vs >9a: 1.8 (1 - 3.3)
Gialluisi 2023	longitudinal	Italy	23,901	ICD	yes	no	no	HIC	HR	primary vs lower secondary: 0.76 (0.5 - 1.15); primary vs post secondary: 0.69 (0.38 - 1.25); primary vs upper secondary: 1.03 (0.72 - 1.49)
Gupta 2014	case-control	India	194	UK PDS BB	no	yes	no	LMIC	OR	illiterate vs others: 0.92 (0.52 - 1.62)
Huang 2023	instrumental variable	European ancestry	482,730		yes	no	yes	HIC	OR	IVW: 1.38 (1.08 - 1.75); EGGER: 1.76 (0.67 - 4.65); WM: 1.26 (0.92 - 1.75); S Mode: 0.74 (0.28 - 1.93); W Mode: 1.04 (0.44 - 2.42)
Jacobs 2020	longitudinal	UK	501,682		yes	no	no	HIC	OR	per year: 0.95 (0.82 - 1.1)
Kuopio 1999	case-control	Finland	369		no	yes	no	HIC	OR	primary vs < upper secondary: 0.89 (0.55 - 1.42); primary vs >= upper secondary: 1.04 (0.5 - 2.19); <10a vs >= 13a: 0.98 (0.42 - 2.27); 11-12a vs >= 13a: 1.16 (0.59 - 2.27)
Kyrozis 2013	longitudinal	Greece	25,407		yes	no	yes	HIC	HR	per 3 years: 0.81 (0.57 - 1.15)
Li 2009	longitudinal	Sweden			no	no	no	HIC	SIR	<9 vs other men: 0.96 (0.94 - 0.99); <9 vs other women: 1.04 (1 - 1.08)
Li 2024	instrumental variable	European ancestry	482,730		yes	no	yes	HIC	OR	IVW: 1.47 (1.21 - 1.78); WM: 1.46 (1.07 - 1.98); EGGER: 1.66 (0.85 - 3.22)
Li 2025	longitudinal	UK	452,492		yes	no	no	HIC	HR	=< A-Levels vs professional/academic degree: 0.98 (0.92 - 1.04)
Llibre-Guerra 2022	cross-sectional	Latin America	12,734	UK PDS BB	yes	yes	no	LMIC	PR	per level (of 5)*: 1.39 (1.03 - 1.89)
Martyn 1995	case-control	UK	515		no	no	no	HIC	OR	Left school <14a vs left school >14a: 0.8 (0.52 - 1.35); Left school <14a vs further education: 0.8 (0.47 - 1.55)
Najafi 2023	case-control	Iran	1,523	MDS	no	yes	no	LMIC	OR	=< primary vs secondary: 1.02 (0.76 - 1.35); =< primary vs academic: 2.17 (1.58 - 2.99)
Osler 2022	longitudinal	Denmark	656,751	ICD	yes	no	no	HIC	HR	7-9a vs 10-11a: 1.03 (0.97 - 1.1); 7-9a vs >=12a: 1.24 (1.14 - 1.35)
Rocca 1996	case-control	Italy	186	study specific	yes	yes	no	HIC	OR	illiterates vs others: 1.9 (0.9 - 4.4); <5a vs others: 1.1 (0.6 - 2.2)
Shi 2022	instrumental variable	European ancestry	482,730		yes	no	yes	HIC	OR	IVW: 1.24 (1.02 - 1.51); EGGER: 1.45 (0.68 - 3.09)
Tan 2007	case-control	China	314	other	no	yes	no	LMIC	OR	=< junior middle vs >= senior middle: 1.63 (0.98 - 2.71)
Taylor 1999	case-control	USA	287	Ward & Gibb	no	no	no	HIC	OR	per year: 0.31 (0.18 - 0.53)
Torti 2020	case-control	Italy	1,166	UK PDS BB	no	no	yes	HIC	OR	primary vs middle: 0.75 (0.51 - 1.1); primary vs high school: 0.87 (0.6 - 1.26); primary vs academic: 0.98 (0.65 - 1.48)
Wijeyekoon 2017	case-control	Sri Lanka	246	UK PDS BB	no	no	yes	LMIC	OR	< A-Levels vs >= A-Levels: 1.92 (0.86 - 4.27)
Wirdefeldt 2005	case-control	Sweden	2,856		yes	no	yes	HIC	OR	compulsory vs > compulsory - external controls: 1.35 (1.05 - 1.75); compulsory vs > compulsory - co-twin controls: 0.94 (0.58 - 1.53)
Zhang 2022	instrumental variable	European ancestry	525,556		yes	no	yes	HIC	OR	IVW: 1.68 (1.07 - 2.62); WM: 1.56 (0.83 - 2.94); EGGER: 0.24 (0.04 - 1.54)
Zou 2015	case-control	China	9,493	UK PDS BB	yes	no	no	LMIC	OR	<7a vs >= 7a: 1.07 (0.82 - 1.41)

ICD = International Classification of Diseases; UK PDS BB = UK Parkinson's Disease Society Brain Bank; MDS = Movement Disorder Society; Ward & Gibb = Research diagnostic criteria for Parkinson's disease by Ward & Gibb 1990; OR = odds ratio; HR = hazard ratio; SIR = standardized incidence ratio; PR = prevalence ratio; IVW = inverse variance weighted; WM = weighted median; S Mode = simple mode; W Mode = weighted mode; * = no education, did not complete primary, completed primary, secondary, or tertiary education

Risk of bias

Most studies (86%) were deemed to be at moderate (n = 15, 43%) or high (n=15, 43%) overall RoB, with only five studies (14%) showing low overall RoB. Each study's domain-specific and overall RoB is tabulated in Table 2 for our main outcome and in Table S3 for our secondary outcome. Figures 3 and 4 show a traffic light plot and a domain-summary RoB plot for our primary outcome, respectively. Please refer to the appendix for plots including removed linked studies (Fig S1) and plots for our secondary outcome (Figs S2-3).

Figure 3: Traffic light plot of the domain-wise and overall RoB of each study included in our main meta-analysis.

Figure 4: Weighted domain-wise RoB of our main analysis.

Table 2

Risk-of-bias judgment for each of six domains of bias, and for the overall risk of bias of studies on our primary outcome

report	Study Participation	Study Attrition	Education Measurement	PD Measurement	Confounding	Statistical Analysis and Reporting	Overall RoB
Achbani 2022	high RoB		low RoB	moderate RoB	moderate RoB	low RoB	moderate RoB
Baldereschi 2003	low RoB		low RoB	low RoB	low RoB	low RoB	low RoB
Chen 2015	moderate RoB	moderate RoB	low RoB	moderate RoB	low RoB	low RoB	moderate RoB
Fardell 2020	moderate RoB	moderate RoB	low RoB	high RoB	low RoB	moderate RoB	high RoB
Frigerio 2005	low RoB		low RoB	moderate RoB	low RoB	low RoB	moderate RoB
Gialluisi 2023	moderate RoB	moderate RoB	low RoB	high RoB	low RoB	low RoB	high RoB
Gupta 2014	moderate RoB		low RoB	low RoB	high RoB	low RoB	high RoB
Huang 2023	moderate RoB		high RoB	moderate RoB	low RoB	low RoB	high RoB
Jacobs 2020	low RoB	moderate RoB	low RoB	high RoB	low RoB	low RoB	high RoB
Kuopio 1999	low RoB		low RoB	low RoB	low RoB	low RoB	low RoB
Kyrozis 2013	low RoB	moderate RoB	low RoB	low RoB	low RoB	low RoB	low RoB
Li 2009	low RoB		low RoB	high RoB	low RoB	low RoB	high RoB
Li 2024	moderate RoB		moderate RoB	moderate RoB	low RoB	low RoB	moderate RoB
Li 2025	low RoB	moderate RoB	low RoB	high RoB	low RoB	moderate RoB	high RoB
Llibre-Guerra 2022	low RoB		low RoB	low RoB	low RoB	moderate RoB	moderate RoB
Martyn 1995	moderate RoB		moderate RoB	high RoB	low RoB	low RoB	high RoB
Najafi 2023	moderate RoB		low RoB	moderate RoB	moderate RoB	high RoB	high RoB
Osler 2022	moderate RoB	moderate RoB	low RoB	high RoB	low RoB	low RoB	high RoB
Rocca 1996	low RoB		low RoB	moderate RoB	low RoB	low RoB	moderate RoB
Shi 2022	moderate RoB		moderate RoB	moderate RoB	low RoB	moderate RoB	moderate RoB
Tan 2007	high RoB		low RoB	low RoB	low RoB	moderate RoB	moderate RoB
Taylor 1999	moderate RoB		low RoB	moderate RoB	low RoB	low RoB	moderate RoB
Torti 2020	high RoB		low RoB	moderate RoB	low RoB	low RoB	moderate RoB
Wijeyekoon 2017	high RoB		low RoB	moderate RoB	low RoB	low RoB	moderate RoB
Wirdefeldt 2005	moderate RoB		moderate RoB	high RoB	high RoB	moderate RoB	high RoB
Zhang 2022	moderate RoB		moderate RoB	high RoB	low RoB	moderate RoB	high RoB
Zou 2015	high RoB		moderate RoB	moderate RoB	high RoB	low RoB	high RoB

RoB = risk of bias; PD = parkinson's disease
Because they reported data from the same study as other reports, Fardell 2020, Huang 2023, Li 2024, Li 2025, Wirdefeldt 2005 were not included in the meta-analysis.

Results of syntheses

Quantitative synthesis of education and the risk of Parkinson's disease

Prior to quantitative synthesis, we linked reports on the same studies and chose the paper with the lowest RoB. Please see the appendix for details on linked reports.

We incorporated 24 studies that investigated the link between educational attainment and the risk of PD in our meta-analysis. Higher education was not significantly associated with higher odds of PD (OR (95% CI) = 1.09 (0.92 – 1.28); p = 0.294; I^2 = 79.5%; absolute risk = 0.14% higher lifetime risk (-0.12% to +0.45%). The heterogeneity between studies was high and included both studies with odds ratios significantly lower and significantly higher than 1. Details are provided in Table 3 and Fig 5 depicts a standard forest plot. Additionally, Fig S4 shows a drapery plot as an alternative illustration of individual studies and the main effect.

Table 3

Results of meta-analyses of all studies

Analysis	n studies	OR (95% CI)	t-/z-value	p-value	prediction interval	tau²	I² (%)	Q / Q'-Q	df	p-value of Q
main	24	1.09 (0.92 - 1.28)	1.075	0.294	0.54 - 2.21	0.111	79.5	111.934	23	0.000
subgroup smoking	24	1.09 (0.92 - 1.28)	1.075	0.294	0.54 - 2.21	0.113	77.7	0.726	1	0.394
smoking not controlled	17	1.04 (0.85 - 1.27)	0.424	0.677	0.5 - 2.18	0.113	76.6	68.442	22	0.000
smoking controlled	7	1.21 (0.84 - 1.73)	1.284	0.247	0.49 - 2.95	0.113	80.2	30.249		0.000
subgroup representative	24	1.09 (0.92 - 1.28)	1.075	0.294	0.54 - 2.21	0.095	72.9	2.667	1	0.102
not representative	10	0.91 (0.65 - 1.29)	-0.589	0.571	0.43 - 1.94	0.095	74.2	34.872	22	0.000
representative	14	1.21 (1.03 - 1.41)	2.579	0.023	0.6 - 2.42	0.095	72.0	46.383		0.000
subgroup PD assessment	24	1.09 (0.92 - 1.28)	1.075	0.294	0.54 - 2.21	0.112	79.3	1.125	1	0.289
not all assessed	16	1.04 (0.83 - 1.3)	0.356	0.726	0.49 - 2.18	0.112	83.9	93.254	22	0.000
all assessed	8	1.21 (0.96 - 1.52)	1.959	0.091	0.51 - 2.87	0.112	47.0	13.205		0.067
subgroup income	24	1.09 (0.92 - 1.28)	1.075	0.294	0.54 - 2.21	0.111	78.4	1.047	1	0.306
HIC	8	1.22 (0.9 - 1.66)	1.574	0.160	0.52 - 2.89	0.111	43.6	12.420	22	0.088
L/MIC	16	1.04 (0.84 - 1.28)	0.365	0.720	0.5 - 2.17	0.111	83.3	89.568		0.000
limit meta-analysis	24	1.11 (0.88 - 0.88)	0.903	0.367		0.111	79.5	11.604	1	0.001

OR (95% CI): Odds ratio with 95% confidence interval (adjusted for limit meta-analysis row); t/z-value: z-value for limit meta-analysis, t-value for all others; p-value: p-value of the effect of education; tau² / I²: measures of heterogeneity for main analysis, measures of residual heterogeneity for overall subgroup analyses, measures of heterogeneity within the subgroup for individual subgroups; Q/Q'-Q/df/p-value of Q = results of test of heterogeneity for main analysis and for individual subgroups, results of test for subgroup differences for overall subgroup analyses, results of test of small-study effects for limit meta-analysis
df = degrees of freedom; HIC = high-income country, L/MIC = low- or middle-income country

Study	logOR	SE(logOR)	Odds Ratio	OR	95%-CI	Weight
Taylor 1999	-1.1786	0.2738		0.31	[0.18; 0.53]	3.3%
Achbani 2022	-0.6579	0.3466		0.52	[0.26; 1.02]	2.7%
Martyn 1995	-0.2231	0.2361		0.80	[0.50; 1.27]	3.7%
Kyrozis 2013	-0.2131	0.1823		0.81	[0.57; 1.16]	4.3%
Torti 2020	-0.1659	0.1688		0.85	[0.61; 1.18]	4.4%
Baldereschi 2003	-0.1523	0.1316		0.86	[0.66; 1.11]	4.8%
Kuopio 1999	-0.0828	0.2385		0.92	[0.58; 1.47]	3.7%
Gupta 2014	-0.0820	0.2890		0.92	[0.52; 1.62]	3.2%
Jacobs 2020	-0.0503	0.0773		0.95	[0.82; 1.11]	5.3%
Gialluisi 2023	-0.0492	0.1744		0.95	[0.68; 1.34]	4.4%
Li 2009	-0.0347	0.0132		0.97	[0.94; 0.99]	5.6%
Osler 2022	0.0596	0.0316		1.06	[1.00; 1.13]	5.5%
Zou 2015	0.0669	0.1381		1.07	[0.82; 1.40]	4.8%
Rocca 1996	0.2376	0.3197		1.27	[0.68; 2.37]	2.9%
Fardell 2020	0.2391	0.0627		1.27	[1.12; 1.44]	5.4%
Najafi 2023	0.2998	0.1372		1.35	[1.03; 1.77]	4.8%
Wirdefeldt 2005	0.3218	0.1298		1.38	[1.07; 1.78]	4.9%
Llibre-Guerra 2022	0.3276	0.1561		1.39	[1.02; 1.88]	4.6%
Li 2024	0.3645	0.0908		1.44	[1.21; 1.72]	5.2%
Chen 2015	0.4195	0.2454		1.52	[0.94; 2.46]	3.6%
Tan 2007	0.4898	0.2594		1.63	[0.98; 2.71]	3.5%
Frigerio 2005	0.5878	0.3046		1.80	[0.99; 3.27]	3.0%
Wijeyekoon 2017	0.6528	0.4077		1.92	[0.86; 4.27]	2.2%
Zhang 2022	0.7591	0.1994		2.14	[1.45; 3.16]	4.1%
Random effects model (HK)				1.09	[0.92; 1.28]	100.0%
Prediction interval					[0.54; 2.21]	

Heterogeneity: $I^2 = 79.5\%$, $p < 0.0001$

Figure 5: Forest plot of our main meta-analysis.

Subgroup analyses

None of the following factors explained a significant share of the heterogeneity: whether studies controlled for smoking, used a representative sample, or assessed all participants. Neither did comparing studies from high- to low- or middle-income countries. Results for each of the subgroup analyses and the respective subgroups are presented in Table 3.

Outliers and influential cases

We detected two outliers (one with a low and one with a high OR). Excluding these two studies did not affect the effect size in a meaningful way but the heterogeneity was reduced slightly (OR (95% CI) = 1.1 (0.98 - 1.24); p = 0.089; I^2 = 73.4%). The subgroup analyses did not differ substantially in this subsample of studies either. Further information can be found in Table S4 and a forest plot is provided in Fig S5.

This is corroborated by a Baujat plot (Fig S6) that also identified these two studies as contributing heavily to the heterogeneity but not to the overall effect size. No study in the Baujat plot contributed heavily to both the heterogeneity and overall effect size. None of our further influence tests (externally standardized residuals, DFFITS value, Cook's distance, Covariance ratio, leave-one-out τ^2 and Q-values, hat value, and study weight) identified any study as particularly influential (Fig S7). Furthermore, 95%

confidence intervals of leave-one-out meta-analyses consistently included 1 (Figs S8-9).

Sensitivity analyses

None of our additional sensitivity analyses (excluding mendelian randomization studies, excluding studies with a high overall RoB, excluding studies reporting effect measures other than OR, including only one Swedish register-based study) led to meaningful differences in either heterogeneity or effect size in the main analysis or the subgroup analyses (Tables S5-8 and Figs S10-13).

Qualitative synthesis of education and Parkinson's disease severity

We identified seven studies that investigated differences in PD patients symptom severity related to education. Only one study that assessed the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale did not find a significant effect of education[76] while five others (two of them with overlapping samples, one including non-idiopathic forms of parkinsonism) found significant associations of higher education with better motor performance[75,77–79,82]. In addition, the former study did find a significantly better performance on the Berg Balance scale amongst more highly educated patients. Furthermore, gait speed was positively linked to education during verbal dual-tasking but not in four other conditions in a Spanish study[81]. Moreover, a longitudinal study of PD patients identified a significantly higher hazard ratio of developing levodopa-induced dyskinesia amongst patients with lower education[78].

Reporting biases

Fig. 6 shows a standard funnel plot of the studies included in our meta-analysis that highlights outliers but does not depict major asymmetry. Due to the high heterogeneity in our main meta-analysis, we performed Rücker's limit meta-analysis and a p-curve analysis on a subset of studies after excluding outliers. The former's test for small study effects was significant ($p = 0.001$) but it also indicated substantial residual heterogeneity beyond small-study effects and the unadjusted and adjusted effect estimates were practically indistinguishable apart from the wider confidence interval of the latter (please see Table 3 for details). A funnel plot showing the shrunken effect sizes is depicted in Fig S14. The p-curve analysis did not find evidence of p-hacking at an estimated power of 59% (test for flatness: $p_{full} = 0.829$, $p_{half} = 0.999$) and indicated the presence of evidence for an actual effect (test for right-skewness: $p_{full} = 0.003$, $p_{half} = 0.002$) but this must be disregarded as the significant p-values stem from studies both indicating significantly higher and significantly lower risk (please also see Fig. S15 and Table S9). The p-curve-based estimate of effect size $d = 0.008$ is miniscule and must be deemed unreliable due to the heterogeneity being >50% even after excluding outliers.

Figure 6: Funnel plot of the studies included in our meta-analysis. The dotted lines are centered around the overall effect size. The successively lighter grey funnels correspond to significance levels of 0.1, 0.05 and 0.01 for the individual studies.

Certainty of evidence

Table 4 depicts the GRADE evidence profile for our primary and secondary outcome.

Table 4

GRADE evidence profile

Outcome	No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	other	Effect of higher education	absolute effect difference	Certainty	Importance
risk of PD	24	observational studies	serious	very serious	not serious	not serious	none	1.09 (0.92 - 1.28)	0.14% higher lifetime risk (from 0.12% lower risk to 0.45% higher risk)	⊕◯◯◯ very low	critical
PD symptom severity	7	observational studies	serious	not serious	not serious	serious	none	better motor performance		⊕⊕◯◯ low	important

PD = parkinson's disease
The provided effect measure is an odds ratio with its 95% confidence interval. The baseline risk is 1.65%.

Education and the risk of Parkinson's disease

As we applied a random-effects meta-analysis, the contribution of each study to the overall certainty of evidence is similar. The best evidence for the effect of educational attainment on the risk of PD is from observational studies. Thus, the design of the included studies does not merit downgrading the certainty of evidence[83,84] and the a priori certainty of evidence is high. Concerns regarding confounding, clarity of eligibility criteria and outcome measurement in some of the studies should result in a downgrade

by one level for risk of bias, though. Furthermore, the large inconsistency in results, that we could not explain by subgroup analyses, led us to downgrade the certainty by two additional levels. The directness of evidence, the availability of very large and precise studies, and the funnel plot symmetry as well as the results of the limit meta-analysis and p-curve spared us from further downgrading for imprecision or publication bias. However, the absence of a large magnitude of effect and a dose-response gradient preclude an increase of the certainty of evidence. Plausible residual confounding is not a reason for greater certainty of evidence, either. Hence, the risk of bias and the inconsistency of results caused us to judge the overall certainty of evidence to be **very low**.

Education and the risk of Parkinson's disease

For our secondary outcome, most judgements are analogous. As the results across studies were rather homogenous, we did not have to downgrade for inconsistency, though. However, the smaller sample sizes and lower number of studies led us to downgrade by one level for imprecision. Thus, the risk of bias and imprecision resulted in an overall judgement of a **low** certainty of evidence for our secondary outcome.

Discussion

This was the first known systematic review and meta-analysis to quantify the association between education and risk of PD. Overall, 36 papers were synthesized and included in this review. The results of our meta-analysis indicate that educational attainment is not linked to the risk of PD in either way. However, the moderate to high RoB of most studies and the high heterogeneity in effect sizes bar us from ruling out that there might be certain circumstances under which there is a positive or negative association. None of the theoretically plausible subgroup analyses revealed such a circumstance, though.

Concerning our secondary outcome, the scarcity of studies and their inconsistent risk of bias preclude definitive conclusions. However, the overall evidence points towards a protective effect of higher education against more severe PD symptoms.

Further evidence

Several reports (e.g. conference abstracts) did not meet our inclusion criteria but should nonetheless be discussed here briefly. As in our meta-analysis, their results are highly heterogenous. Three reports found significantly higher education amongst cases when compared to controls[46,48,85]. Additionally, Yang et al. 2014 found a lower PD incidence in persons with low socioeconomic status[50] and two mendelian randomization studies reported a positive association of IQ and PD risk[86,87]. However, four other studies, did not find significant differences by educational attainment[42,43,45,88] and two reported significantly higher education in controls compared to cases[47,89]. Moreover, a study using dopamine transporter SPECT did not find significant differences by education level

in tolerance against dopamine loss in PD[90]. In contrast, reports that did not meet our inclusion criteria that are relevant to our secondary outcome are well aligned. Lirani-Silva et al. 2017, Sohn et al. 2016 and Kotagal et al. 2015 all found worse motor symptoms amongst PD patients with lower educational attainment[49,79,91]. Some of these reports are linked to included studies, though.

Limitations

We screened 23,648 reports and thus conducted a very extensive search of the literature. Yet, we cannot rule out that some relevant evidence might still have been missed due to location or language bias. However, these biases tend to reduce effect sizes and as we did not find an effect in either direction, this is less of a concern than in other circumstances. Another potential limitation of the review is that we could not perform dual title and abstract screening for all reports due to resource constraints. We did complete dual screening and extractions for all other stages, though and for over 5000 citations at title and abstract screening with an agreement of over 99% which makes us confident that the reliability of our findings is not hampered by this.

Conclusions and outlook

Education is thought to influence health through various pathways. A key factor seems to be higher income with the resulting improved living conditions and better access to healthcare. Furthermore, safer working environments, salubrious behaviours and decisions, and beneficial effects of societal status and social networks are all likely to contribute to the positive effect of education on health[92,93]. However, all these mechanisms are believed to contribute to better health and hence cannot explain a higher risk of PD amongst more educated individuals.

Most studies that provided a hypothesis on why education was positively linked to risk of PD in their analyses attributed the association to increased health literacy and/or better access to healthcare amongst more highly educated individuals leading to more undiagnosed cases of PD amongst persons with lower educational attainment[15,72,80]. This is similar to the hypothesis that the lower prevalence of PD diagnoses in Blacks compared to Whites in the USA, despite no difference in Lewy body burden[94], could be explained by disparities in access to health care[1,95]. The results for our secondary outcome are compatible with this notion, too. The greater symptom severity amongst patients with lower education could result from receiving a diagnosis only after more pronounced disease progression. Furthermore, this hypothesis is indirectly supported by evidence showing higher risk of PD in healthcare professionals[12,39,96], who would be expected to have exceptional health literacy, and increased diagnostic latency amongst patients without health insurance[97]. Furthermore, the general underdiagnosis of PD elucidated by the high rates of new diagnoses in door-to-door prevalence studies[98,99] adds to its plausibility.

However, there is no high-quality evidence on an association of education and diagnostic latency and all available studies did not find a significant link[100–103]. To test for quantitative evidence for this hypothesis, we aimed to explain some of the heterogeneity in effect sizes by categorizing studies in line with it. These subgroup analyses did not yield evidence supporting this hypothesis, though. However, we could only investigate this in a rather indirect manner and this must thus not be interpreted as any refutation of the hypothesis. Further research should explicitly measure health literacy and access to healthcare when investigating the link of education and the risk of PD.

An alternative explanation of the observed positive associations could be the negative associations of educational level with smoking and of smoking with risk of PD[7]. However, our subgroup analysis testing this did not explain much of the heterogeneity in effect sizes either.

Alternatively, the numerous significant results reported despite an effect close to unity in our meta-analysis might be explained statistically. Only 2 of the 24 studies included in the meta-analysis controlled for multiple comparisons although all studies investigated multiple risk factors. Moreover, although our meta-analysis does not seem to have been affected by small study effects, bias might still have distorted the image painted by some of the reports. Namely, many reports tested the effect of education on the risk of PD in various ways of which some were significant and others were not. Yet, in discussing their results, the reports highlighted the significant results and disregarded the insignificant tests. Lastly, the high heterogeneity in the operationalization of education might have additionally contributed to the heterogeneity in results. Henceforth, a combination of operationalization heterogeneity, type-I error inflation and selective emphasis might be the best explanation for the purported association of education and the risk of PD. Taken all together, this systematic review and meta-analysis does not support the hypothesis that higher educational attainment is associated with an increased risk of Parkinson's disease.

Data availability statement

All data used for the meta-analysis is available at https://osf.io/j9hp2. The script available at https://github.com/LaurenzLammer/pd_education_ma automatically loads this data.

Authors roles

LL: Conceptualization, Data Curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

CPP: Conceptualization, Data Curation, Methodology, Writing – Review & Editing

MK: Data Curation, Validation, Writing – Review & Editing

AS: Data Curation, Writing – Review & Editing

SB: Conceptualization, Data Curation, Methodology, Supervision, Writing – Review & Editing

References

1.   Ben-Shlomo, Y. *et al.* The epidemiology of Parkinson's disease. *The Lancet* vol. 403 283–292 Preprint at https://doi.org/10.1016/S0140-6736(23)01419-8 (2024).

2.   Steinmetz, J. D. *et al.* Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Neurol* **23**, 344–381 (2024).

3.   Dorsey, E. R., Sherer, T., Okun, M. S. & Bloemd, B. R. The emerging evidence of the Parkinson pandemic. *J Parkinsons Dis* **8**, S3–S8 (2018).

4.   Foltynie, T. *et al.* Medical, surgical, and physical treatments for Parkinson's disease. *The Lancet* vol. 403 305–324 Preprint at https://doi.org/10.1016/S0140-6736(23)01429-0 (2024).

5.   Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson's disease. *The Lancet* vol. 403 293–304 Preprint at https://doi.org/10.1016/S0140-6736(23)01478-2 (2024).

6.   Bloem, B. R., Okun, M. S. & Klein, C. Parkinson's disease. *The Lancet* vol. 397 2284–2303 Preprint at https://doi.org/10.1016/S0140-6736(21)00218-X (2021).

7.   Bellou, V., Belbasis, L., Tzoulaki, I., Evangelou, E. & Ioannidis, J. P. A. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. *Parkinsonism Relat Disord* **23**, 1–9 (2016).

8.   Zhang, D., Jiang, H. & Xie, J. Alcohol intake and risk of Parkinson's disease: A meta-analysis of observational studies. *Movement Disorders* **29**, 819–822 (2014).

9.   Park, J. *et al.* Occupations and Parkinson's disease: A multi-center case-control study in South Korea. *Neurotoxicology* **26**, 99–105 (2005).

10.   Marder, K. *et al.* Environmental risk factors for Parkinson's disease in an urban multiethnic community. *Neurology* **50**, 179–281 (1998).

11.   Najafi, F. *et al.* Association between socioeconomic status and Parkinson's disease: Findings from a large incident case-control study. *BMJ Neurol Open* **5**, 1–8 (2023).

12.   Frigerio, R. *et al.* Education and occupations preceding Parkinson disease. *Neurology* **65**, 1575–1583 (2005).

13. Shi, J. *et al*. Intelligence, education level, and risk of Parkinson's disease in European populations: A Mendelian randomization study. *Front Genet* **13**, 1–8 (2022).

14. Dorsey, E. R. *et al*. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* **17**, 939–953 (2018).

15. Rocca, W. A. *et al*. Occupation, Education, and Parkinson's Disease: A Case-Control Study in an Italian Population. *Movement Disorders* **11**, 201–206 (1996).

16. Jacobs, B. M. *et al*. Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. *J Neurol Neurosurg Psychiatry* **91**, 1046–1054 (2020).

17. Li, X., Sundquist, J. & Sundquist, K. Socioeconomic and occupational groups and Parkinson's disease: A nationwide study based on hospitalizations in Sweden. *Int Arch Occup Environ Health* **82**, 235–241 (2009).

18. Taylor, C. A. *et al*. Environmental, medical, and family history risk factors for Parkinson's disease: A new England-based case control study. *American Journal of Medical Genetics - Neuropsychiatric Genetics* **88**, 742–749 (1999).

19. Page, M. J. *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* **372**, (2021).

20. Borenstein, M., V.Hedges, L., Higgins, J. P. T. & Rothstein, H. R. *Introduction to Meta-Analysis*. (2009).

21. Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* **5**, (2016).

22. Saldanha, I. J. *et al*. The Systematic Review Data Repository (SRDR): Descriptive characteristics of publicly available data and opportunities for research. *Syst Rev* **8**, (2019).

23. Haynes, R. B., Kastner, M. & Wilczynski, N. L. Developing optimal search strategies for detecting clinically sound and relevant causation studies in EMBASE. *BMC Med Inform Decis Mak* **5**, (2005).

24. McGowan, J. *et al*. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol* **75**, 40–46 (2016).

25. Li, T., Higgins, J. & Deeks, J. Chapter 5: Collecting data [last updated October 2019]. in *Cochrane Handbook for Systematic Reviews of Interventions version 6.5* (eds. Higgins, J. et al.) (Cochrane, 2024).

26.   Hayden, J. A., Windt, D. A. Van Der, Cartwright, J. L. & Co, P. Assessing Bias in Studies of Prognostic Factors. *Ann Intern Med* **158**, 280–286 (2013).

27.   Morissette, K., Tricco, A. C., Horsley, T., Chen, M. H. & Moher, D. Blinded versus unblinded assessments of risk of bias in studies included in a systematic review. *Cochrane Database of Systematic Reviews* (2011) doi:10.1002/14651858.MR000025.pub2.

28.   Chinn, S. A simple method for converting an odds ratio to effect size for use in meta-analysis. *Stat Med* **19**, 3127–3131 (2000).

29.   Paule, R. C. & Mandel, J. Consensus Values and Weighting Factors. *Journal of ResearchH of the National Bureau of Standards* **87**, (1982).

30.   Knapp, G. & Hartung, J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med* **22**, 2693–2710 (2003).

31.   Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. *Stat Med* **21**, 1539–1558 (2002).

32.   Harrer, M., Cuijpers, P., A, F. T. & Ebert, D. D. *Doing Meta-Analysis With R: A Hands-On Guide*. (Chapman & Hall/CRC Press, Boca Raton, FL and London, 2021).

33.   Tamhane, A. R., Westfall, A. O., Burkholder, G. A. & Cutter, G. R. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. *Stat Med* **35**, 5730–5735 (2016).

34.   Hultcrantz, M. *et al*. The GRADE Working Group clarifies the construct of certainty of evidence. *J Clin Epidemiol* **87**, 4–13 (2017).

35.   The GRADE Working Group. *GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations*. (2013).

36.   The GRADE Working Group. *GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations*. (2013).

37.   Morgan, R. L. *et al*. A risk of bias instrument for non-randomized studies of exposures: A users' guide to its application in the context of GRADE. *Environ Int* **122**, 168–184 (2019).

38.   Foroutan, F. *et al*. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. *J Clin Epidemiol* **121**, 62–70 (2020).

39.   Driver, J. A., Logroscino, G., Gaziano, J. M. & Kurth, T. *Incidence and Remaining Lifetime Risk of Parkinson Disease in Advanced Age*. (2009).

40.   Elbaz, A. *et al*. Risk tables for parkinsonism and Parkinson's disease. *J Clin Epidemiol* **55**, 25–31 (2002).

41. Zhang, J. & Yu, K. F. *What's the Relative Risk? A Method of Correcting the Odds Ratio in Cohort Studies of Common Outcomes*. *JAMA* vol. 280 http://jama.jamanetwork.com/ (1998).

42. Dick, F. D. *et al*. Environmental risk factors for Parkinson's disease and parkinsonism: The Geoparkinson study. *Occup Environ Med* **64**, 666–672 (2007).

43. Nicoletti, A. *et al*. The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features. *Neurological Sciences* **31**, 47–52 (2010).

44. Torrealba-Acosta, G. *et al*. Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease. *Front Neurol* **12**, (2021).

45. Georgiou, A. *et al*. Genetic and environmental factors contributing to parkinson's disease: A case-control study in the cypriot population. *Front Neurol* **10**, (2019).

46. Marder, K. *et al*. Environmental risk factors for Parkinson's disease in an urban multiethnic community. *Neurology* **50**, 179–281 (1998).

47. Belvisi, D. *et al*. Risk factors of Parkinson disease Simultaneous assessment, interactions, and etiologic subtypes. *Neurology* **95**, E2500–E2508 (2020).

48. Alcalay, R. N. *et al*. The association between Mediterranean diet adherence and Parkinson's disease. *Movement Disorders* **27**, 771–774 (2012).

49. Sohn, Y. H., Sunwoo, M. K. & Lee, P. H. Does premorbid educational attainment modify motor compensation in Parkinson's Disease? *Parkinsonism Relat Disord* **22**, e65 (2016).

50. Yang, F. *et al*. Socioeconomic status in relation to Parkinson's disease risk and mortality: A population-based prospective study. *Medicine (United States)* **95**, (2016).

51. Cochrane Effective Practice and Organisation of Care. Which studies should be included in the "Characteristics of excluded studies" table? EPOC Resources for review authors. (2017).

52. Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E. & Rocca, W. A. Risk factors for Parkinson's disease may differ in men and women: An exploratory study. *Hormones and Behavior* vol. 63 308–314 Preprint at https://doi.org/10.1016/j.yhbeh.2012.05.013 (2013).

53. Achbani, A. *et al*. Risk Factors of Parkinson's Disease: A Case-Control Study in Moroccan Patients. *Arch Neurosci* **9**, (2022).

54.	Baldereschi, M. *et al*. Lifestyle-related risk factors for Parkinson's disease: a population-based study. *Acta Neurol Scand* (2003) doi:10.1046/j.1600-0404.2003.00128.x.

55.	Chen, H. *et al*. Parkinson's disease research in a prospective cohort in China. *Parkinsonism Relat Disord* **21**, 1200–1204 (2015).

56.	Fardell, C., Torén, K., Schiöler, L., Nissbrandt, H. & Aberg, M. High IQ in Early Adulthood Is Associated with Parkinson's Disease. *J Parkinsons Dis* **10**, 1649–1656 (2020).

57.	Gialluisi, A. *et al*. Risk and protective factors in Parkinson's disease: a simultaneous and prospective study with classical statistical and novel machine learning models. *J Neurol* **270**, 4487–4497 (2023).

58.	Gupta, V., Kumar Garg, R., Kumar Pant, K. & Khattri, S. A study on risk factors for Parkinson's disease in Indian population. *Bioinformation* **10**, 342–346 (2014).

59.	Huang, L. Y. *et al*. Associations of cardiovascular risk factors and lifestyle behaviors with neurodegenerative disease: a Mendelian randomization study. *Transl Psychiatry* **13**, (2023).

60.	Shi, J. *et al*. Intelligence, education level, and risk of Parkinson's disease in European populations: A Mendelian randomization study. *Front Genet* **13**, 1–8 (2022).

61.	Zhang, R. Q. *et al*. Shared polygenic risk and causal inferences in Parkinson's disease. *Brain Disord* **7**, (2022).

62.	Kuopio, A. M., Marttila, R. J., Helenius, H. & Rinne, U. K. Environmental risk factors in Parkinson's disease. *Movement Disorders* **14**, 928–939 (1999).

63.	Kyrozis, A. *et al*. Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece. *Eur J Epidemiol* **28**, 67–77 (2013).

64.	Li, D. *et al*. Associations of environmental factors with neurodegeneration: An exposome-wide Mendelian randomization investigation. *Ageing Research Reviews* vol. 95 Preprint at https://doi.org/10.1016/j.arr.2024.102254 (2024).

65.	Li, P. *et al*. Joint effect of modifiable risk factors on Parkinson's disease: a large-scale longitudinal study. *Front Hum Neurosci* **19**, (2025).

66.	Llibre-Guerra, J. J. *et al*. Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study. *The Lancet Regional Health - Americas* **7**, 100136 (2022).

67.	Martyn, C. N. & Osmond, C. Parkinson's disease and the environment in early life. *J Neurol Sci* **132**, 201–206 (1995).

68. Osler, M., Okholm, G. T., Villumsen, M., Rozing, M. P. & Jørgensen, T. S. H. Associations of Young Adult Intelligence, Education, Height, and Body Mass Index with Subsequent Risk of Parkinson's Disease and Survival: A Danish Cohort Study. *J Parkinsons Dis* **12**, 1035–1043 (2022).

69. Tan, X. Risk factors for Parkinson disease and the path analysis: One-to-one paired design. *Neural Regen Res* **2**, 117–120 (2007).

70. Taylor, C. A. *et al.* Environmental, medical, and family history risk factors for Parkinson's disease: A new England-based case control study. *American Journal of Medical Genetics - Neuropsychiatric Genetics* **88**, 742–749 (1999).

71. Torti, M. *et al.* Effect of family history, occupation and diet on the risk of Parkinson disease: A casecontrol study. *PLoS One* **15**, (2020).

72. Wijeyekoon, R. *et al.* Associations Between Lifestyle Factors And Parkinson's Disease In An Urban Sri Lankan Clinic Study. *Int Arch Med* **10**, (2017).

73. Wirdefeldt, K., Gatz, M., Pawitan, Y. & Pedersen, N. L. Risk and protective factors for Parkinson's disease: A study in Swedish twins. *Ann Neurol* **57**, 27–33 (2005).

74. Zou, Y. M. *et al.* Do physical exercise and reading reduce the risk of parkinson's disease? A cross-sectional study on factors associated with parkinson's disease in elderly Chinese veterans. *Neuropsychiatr Dis Treat* **11**, 695–700 (2015).

75. Blume, J., Rothenfusser, E., Schlaier, J., Bogdahn, U. & Lange, M. Educational attainment and motor burden in advanced Parkinson's disease – The emerging role of education in motor reserve. *J Neurol Sci* **381**, 141–143 (2017).

76. De, C. *et al. Influence of Educational Status on Executive Function and Functional Balance in Individuals with Parkinson Disease*. http://journals.lww.com/cogbehavneurol (2013).

77. Hemming, J. P. *et al.* Racial and socioeconomic disparities in parkinsonism. *Arch Neurol* **68**, 498–503 (2011).

78. Jeong, S. H. *et al.* Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson's Disease. *J Parkinsons Dis* **12**, 129–136 (2022).

79. Kotagal, V. *et al.* Educational attainment and motor burden in Parkinson's disease. *Movement Disorders* **30**, 1143–1147 (2015).

80. Martínez-Rumayor, A., Arrieta, O., Sotelo, J. & García, E. Female gender but not cigarette smoking delays the onset of Parkinson's disease. *Clin Neurol Neurosurg* **111**, 738–741 (2009).

81. San Martín Valenzuela, C., Dueñas, L., Tomás, J. M., Correa-Ghisays, P. & Serra-Añó, P. Relevance of Sociodemographics and Clinical Tests in Single-and Dual-

Task Conditions as Gait Speed Predictors of Parkinson's Disease. *J Clin Med* **11**, (2022).

82. Sunwoo, M. K., Hong, J. Y., Lee, J. J., Lee, P. H. & Sohn, Y. H. Does education modify motor compensation in Parkinson's disease? *J Neurol Sci* **362**, 118–120 (2016).

83. Morgan, R. L. *et al*. A risk of bias instrument for non-randomized studies of exposures: A users' guide to its application in the context of GRADE. *Environ Int* **122**, 168–184 (2019).

84. Foroutan, F. *et al*. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. *J Clin Epidemiol* **121**, 62–70 (2020).

85. Weisskopf, M. G. *et al*. Prospective Study Of Education, Occupation, and Risk of Parkinson's Disease. *Am J Epidemiol* **163**, S178–S178 (2006).

86. Longinetti, E. *et al*. Heart rate, intelligence in adolescence, and Parkinson's disease later in life. *Eur J Epidemiol* **36**, 1055–1064 (2021).

87. Jing, C., Zhong, X., Min, X. L. & Xu, H. The causal effects of intelligence and fluid intelligence on Parkinson's disease: a Mendelian randomization study. *Front Aging Neurosci* **16**, (2024).

88. Firestone, J. A. *et al*. Occupational factors and risk of Parkinson's disease: A population-based case-control study. *Am J Ind Med* **53**, 217–223 (2010).

89. Zhu, A. & Liang, Y. Risk factors for Parkinson's disease and Parkinson's disease with cognitive impairment in high altitude: A case-control study. *Parkinsonism Relat Disord* **122**, (2024).

90. Hoenig, M. C. *et al*. Educational level and its association with dopamine transporter loss in patients with Parkinson's disease. *Parkinsonism Relat Disord* **115**, 105844 (2023).

91. Lirani-Silva, E. *et al*. Effects of education level on motor and non-motor symptoms of Brazilian patients with Parkinson's disease. in (2017).

92. Richard Desjardins & Tom Schuller. *Measuring the Effects of Education on Health and Civic/Social Engagement*. (2006).

93. Cutler, D. & Lleras-Muney, A. *Education and Health: Evaluating Theories and Evidence*. *Making Americans Healthier: Social and Economic Policy as Health Policy* vol. 12352 (2006).

94. Nag, S. *et al*. Association of Lewy Bodies With Age-Related Clinical Characteristics in Black and White Decedents. *Neurology* **97**, E825–E835 (2021).

95. de Lau, L. M. & Breteler, M. M. The epidemiology of Parkinson's disease. *Lancet Neurology* **5**, 525–535 (2006).

96. Joseph K.C. Tsui ... *Occupational Risk Factors in Parkinson's Disease*.

97. Surathi, P. & Feinstein, E. Socio-economic determinants of diagnostic latency in Parkinson's disease patients. in (2020).

98. de Rijk, M. C. *et al.* Prevalence of Parkinson's Disease in the elderly: The Rotterdam Study. *Neurology* **45**, 2143–2146 (1995).

99. Benito-León, J. *et al.* Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. *Movement Disorders* **18**, 267–274 (2003).

100. Lay-Son, L., Eloiza, C. & Trujillo-Godoy, O. Latencia diagnóstica en la enfermedad de Parkinson: Estudio en 200 pacientes de novo en un hospital público de Chile. *Rev Med Chil* **143**, 870–873 (2015).

101. C. Rodriguez-Alarcon, D. Piana-Castillo, G. Faggioni-Sanchez, D. Bustamante-Mieles, M. Barreiro-Guillén, C. Cevallos-Velasco, R. S.-V. Education Levels on Diagnostic Delay Phase and Initial Symptom Perception Among Hispanic Patients with Parkinson's Disease: A Cross-Sectional Study. in (2024).

102. Breen, D. P., Evans, J. R., Farrell, K., Brayne, C. & Barker, R. A. Determinants of delayed diagnosis in Parkinson's disease. *J Neurol* **260**, 1978–1981 (2013).

103. Ruiz-mafud, M. A., Ichikawa-escamilla, E., Reséndiz-henríquez, E. & Cerda-hernández, G. I. IMPACT OF EDUCATIONAL LEVEL ON DELAYED DIAGNOSIS IN MEXICAN PEOPLE LIVING WITH PARKINSON'S DISEASE. 2–3 (2023) doi:10.13140/RG.2.2.17260.74883.

104. The World Bank. *World Development Indicators: The World by Income and Region* . (2025).

105. Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* **50**, 1112–1121 (2018).

106. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* **18**, 1091–1102 (2019).

107. Rietveld, C. A. *et al.* GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational Attainment. *Science (1979)* **340**, 1467–1471 (2013).

Appendix

Database searches

PubMed

The search was performed on the 6th of March 2025.

("Educational Status"[Mesh:NoExp] OR "Education*"[tiab] OR "Academic*" [tiab] OR "Social Class"[Mesh] OR "social class*"[tiab] OR "Socioeconomic Status"[tiab] OR "Socioeconomic Level*"[tiab] OR "Social gradient*"[tiab] OR "Epidemiologic Factors"[Mesh:NoExp] OR "Epidemiologic* Factor*"[tiab] OR "Determinant*"[tiab] OR "behavio* risk factor*"[tiab] OR "environmental risk factor*"[tiab] OR "Social Determinants of Health/statistics and numerical data"[Mesh])

AND ("Parkinson Disease"[Mesh] OR "Parkinson*" [tiab])

NOT ("Animals"[Mesh] NOT "Humans"[Mesh])

NOT ("Review"[pt] OR "Meta-Analysis" [pt] OR "Case Reports" [pt] OR "Clinical Study"[pt] OR "Comment"[pt] OR "Editorial"[pt] OR "Consensus Development Conference"[pt] OR "Guideline"[pt] OR "Evaluation Study"[pt])

PsychInfo

The search was performed on the 6th of March 2025.

((Education/ or Academic Achievement/ or Education*.ti,ab. or exp Socioeconomic Status/ or social class*.ti,ab. or Socioeconomic Status.ti,ab. or Socioeconomic Level*.ti,ab. or Social gradient*.ti,ab. or Epidemiology/ or Epidemiologic* Factor*.ti,ab. or behavio* risk factor*.ti,ab. or environmental risk factor*.ti,ab. or Social Determinants of Health/) and (exp "Parkinsons Disease"/ or Parkinson*.ti,ab.))

not (exp animal*/ or exp invertebrates/ or exp vertebrates/ or exp mice/ or exp "plant (botanical)"/)

not (exp Clinical Trial*/ or Meta Analysis/ or exp Literature Review/ or Treatment Guidelines/ or Case Report/ or exp Evaluation/)

not (Bibliography or "Column/Opinion" or "Comment/Reply" or Encyclopedia Entry or Interview or Editorial or Letter or Obituary or Poetry or Review-Book or Review-Media or Review-Software & Other or "Journal Column/Opinion" or Journal Column or Journal Editorial or Journal Editorials or Journal Information or Journal Letter or Journal Letters or Journal Obituaries or Journal Obituary or Journal Review-Book or Journal Review-Books or Journal Review-Other or "Journal Review-Software/Video/Other" or Journal Review-Software or Journal Review-Video).dt.

Web of Science

The search was performed on the 7th of March 2025.

(TS=Education* OR TS=Academic* OR TS=Social Class* OR TS=Socioeconomic Status OR TS=Socioeconomic Level* OR TS=Social gradient* OR TS=Epidemiologic Factor* OR TS=Determinant* OR TS=behavio* risk factor* OR TS=environmental risk factor* OR TS=Social Determinants of Health)

AND (TS=Parkinson*)

NOT ((TS=Animal* OR TS=mice OR TS=Rats) NOT TS=Human*)

NOT ((TS=Child* OR TS=Infant OR TS=Adolescents) NOT TS=Adult)

NOT (TS=Review OR TS=Meta-Analysis OR TS=Case Report* OR TS="case series" OR TS="Clinical Study" OR TS=intervention OR TS=RCT OR TS=Comment OR TS=Editorial OR TS=Consensus OR TS=Guideline OR TS="Evaluation study" OR TS=Patent OR TS="Editorial Material" OR TS="Clinical Trial" OR TS=Letter OR TS=Book OR TS=News OR TS=Biography OR TS="Review Article" OR TS=Meeting OR TS=Correction OR TS="Retracted Publication")

NOT (LA=Spanish OR LA=French OR LA=Czech OR LA=Turkish OR LA=Portuguese OR LA=Hungarian OR LA=Italian OR LA=Polish OR LA=Russian OR LA=Korean OR LA=Persian OR LA=Croatian OR LA=Japanese) and Review Article or Editorial Material or Book Review or Retracted Publication or Data Paper or Music Performance Review (Exclude – Document Types)

Embase

The search was performed on the 7th of March 2025.

((exp education/ or exp educational status/ or 'education'.ab,kw,ti. or exp academic achievement/ or exp social class/ or 'social class'.ab,kw,ti. or exp socioeconomic status/ or 'socioeconomic status'.ab,kw,ti. or exp social determinants of health/ or 'social determinants of health'.ab,kw,ti. or 'behavioural risk factor'.ab,kw,ti. or 'behavioral risk factor'.ab,kw,ti. or 'epidemiological factor*'.ab,kw,ti. or exp social status/)

and (exp Parkinson disease/ or 'Parkinson disease'.ab,kw,ti.))

not (exp animal/ not exp human/)

not (Conference review or Books or editorial or erratum or letter or note or Review or Short survey).pt.

limit 1 to (human and (english or german))

Extracted information

We collected data on:

- Metadata: extractor, extraction date, extraction version number, title, author(s), date of publication, doi and/or other identifier(s)
- Participants: Total number of participants (number of cases and controls, at each timepoint, if applicable), setting, geographical location, study eligibility criteria, descriptive statistics
- Education: assessment method, variable type with cut-offs
- PD: Ascertainment method, assessor qualification, diagnostic criteria, symptom severity assessment method, timepoint of assessment
- Study design: study name, general study design, recruitment and sampling procedures, enrolment start and end dates, length of follow-up (if applicable), methods used to prevent and control for confounding, information biases, measures taken to control selection biases, preregistration, preventing/handling missing data
- Statistical analysis: unit of analysis, statistical methods, multiplicity control, a priori power calculation
- Results: summary data, between-group estimates with precision
- Other: funding, conflicts of interest, key conclusions of the study authors, need for correspondence, miscellaneous comments

Country wise income categorization

Our categorizations were based on The World Bank's World Development Indicators[104]. High income countries were dichotomously distinguished from all other categories. Due to the high missingness of information on and heterogeneity in recruitment times, we used the publication year to discern the appropriate category for each study's population. A study with samples from numerous Latin American countries was summatively categorized in the low- and middle-income group and mendelian randomization studies of participants of European ancestry were grouped in the high-income category.

Effect size homogenization

If education was treated as a continuous variable with the metric e.g. in years of schooling, we assumed the average difference in years of schooling between the low and the high education group to be five years. Accordingly, the OR per year of schooling was converted: $OR_{p.a.}^{5} = OR_{dichotomous}$. Likewise, if education was coded in levels and effect sizes were provided per level the effect size was taken to the power of n (of levels) / 2. If there were 3 levels, this would mean $OR_{per\ level}^{1.5} = OR_{dichotomous}$.

[11,15,53,55–57,62,68,71,73] provided ORs from multiple comparisons that were aggregated using the aggregate function of **{metafor}** setting ρ (the correlation of the sampling errors) to 0.6.

[59–61,64] provided mendelian randomization based OR estimates derived from different methods. These estimates were also aggregated using the aggregate function of **{metafor}** setting ρ (the correlation of the sampling errors) to 0.6.

ORs for [58,74] were calculated from raw count data of cases and controls using the oddsratio() function of **{epitools}** employing the default median-unbiased estimation.

ORs and confidence intervals for [64] were calculated from beta coefficients and SEs from logistic regression using the following formulae: $OR = e^{beta}$. Lower limit = $e^{beta - 1.96 * SE}$. Upper limit = $e^{beta + 1.96 * SE}$.

Standard errors for studies that reported ORs with p-values [65,69] were calculated using: $SE = \log(OR) / z$, where z is the quantile from the standard normal distribution of $1 - p/2$.

[17] provided standardized incidence ratios for different education levels. Using either that for <9 years or that for >16 years would clearly indicate the direction of the effect. As the <9 years group is more than 10 times as large as the >16 years group we chose the former as our measure of effect size for this study. The separate effect estimates for men and women were aggregated as in the other studies.

Linked reports

Both [12] and [52] are based on the Rochester Epidmiology project. For the meta-analysis we included Frigerio et al. as Savica et al.'s gender stratified analysis did not fit our research question as well.

Both [16] and [65] used data from the UK Biobank. As preregistered, we based our choice on the RoB as determined by the QUIPS tool. This led us to choose Jacobs et al.

[17,56,73] are based on overlapping Swedish registries. As the samples are merely overlapping, we included all studies in our main analysis but conducted a sensitivity analysis only including the Swedish register-based study with the lowest RoB (Li et al. 2009).

Furthermore, three mendelian randomization studies[59,60,64] were based on GWAS from the same studies (education is based on:[105]; PD is based on: [106]). Of these studies we chose Li et al. based on its RoB. Additionally, [61] also relied on [106] for the PD GWAS but used [107] for the education GWAS and was hence included in the MA.

Moreover, both [82] and [78] are based on the Yonsei Parkinson Center database. As both studies only concern our secondary outcome, that is not analysed meta-analytically, this was discussed in the narrative summary.

All studies (except for Savica et al. 2013 because of bad fit with research question) are maintained in the published dataset so that other researchers can explore the impact of including/excluding individual studies.

Supplementary Figures

Supplementary Figure 1: Traffic light plot of domain-wise and overall RoB of all reports relevant to our primary outcome including linked reports.

Supplementary Figure 2: Traffic light plot of studies relevant to our secondary outcome.

Supplementary Figure 3: Unweighted domain-wise RoB for our secondary outcome.

Supplementary Figure 4: Drapery plot of our main meta-analysis. The dashed lines indicate different levels of significance. The thin grey lines indicate the effects of individual studies and the thicker red line represents the overall effect.

Study	logOR	SE(logOR)	Odds Ratio	OR	95%-CI	Weight
Achbani 2022	-0.6579	0.3466		0.52	[0.26; 1.02]	1.9%
Martyn 1995	-0.2231	0.2361		0.80	[0.50; 1.27]	3.2%
Kyrozis 2013	-0.2131	0.1823		0.81	[0.57; 1.16]	4.3%
Torti 2020	-0.1659	0.1688		0.85	[0.61; 1.18]	4.6%
Baldereschi 2003	-0.1523	0.1316		0.86	[0.66; 1.11]	5.5%
Kuopio 1999	-0.0828	0.2385		0.92	[0.58; 1.47]	3.2%
Gupta 2014	-0.0820	0.2890		0.92	[0.52; 1.62]	2.5%
Jacobs 2020	-0.0503	0.0773		0.95	[0.82; 1.11]	7.0%
Gialluisi 2023	-0.0492	0.1744		0.95	[0.68; 1.34]	4.5%
Li 2009	-0.0347	0.0132		0.97	[0.94; 0.99]	8.1%
Osler 2022	0.0596	0.0316		1.06	[1.00; 1.13]	7.9%
Zou 2015	0.0669	0.1381		1.07	[0.82; 1.40]	5.4%
Rocca 1996	0.2376	0.3197		1.27	[0.68; 2.37]	2.2%
Fardell 2020	0.2391	0.0627		1.27	[1.12; 1.44]	7.4%
Najafi 2023	0.2998	0.1372		1.35	[1.03; 1.77]	5.4%
Wirdefeldt 2005	0.3218	0.1298		1.38	[1.07; 1.78]	5.6%
Llibre-Guerra 2022	0.3276	0.1561		1.39	[1.02; 1.88]	4.9%
Li 2024	0.3645	0.0908		1.44	[1.21; 1.72]	6.7%
Chen 2015	0.4195	0.2454		1.52	[0.94; 2.46]	3.1%
Tan 2007	0.4898	0.2594		1.63	[0.98; 2.71]	2.9%
Frigerio 2005	0.5878	0.3046		1.80	[0.99; 3.27]	2.3%
Wijeyekoon 2017	0.6528	0.4077		1.92	[0.86; 4.27]	1.5%
Random effects model (HK)				**1.10**	**[0.98; 1.24]**	**100.0%**
Prediction interval					**[0.73; 1.67]**	

Heterogeneity: $I^2 = 73.4\%$, $p < 0.0001$

Supplementary Figure 5: Forest plot of the meta-analysis excluding outliers.

Supplementary Figure 6: Baujat plot of the studies included in our main meta-analysis. The circle diameter corresponds to the studies relative weight.

Supplementary Figure 7: Depictions of multiple measures of individual study influence. Influential cases would be depicted in red but there are none.

Sorted by Effect Size

Supplementary Figure 8: Results of leave-one-out meta-analyses sorted by effect size.

Supplementary Figure 9: Results of leave-one-out meta-analyses sorted by I^2.

Supplementary Figure 10: Forest plot of meta-analysis excluding studies at high RoB.

Supplementary Figure 11: Forest plot of meta-analysis excluding mendelian randomization studies.

Supplementary Figure 12: Forest plot of meta-analysis excluding studies reporting effect measures other than OR.

Supplementary Figure 13: Forest plot of meta-analysis including only the Swedish register-based study with the lowest RoB.

Supplementary Figure 14: Funnel plot of the limit meta-analysis excluding outlying studies. Circles depict original effect sizes and squares the effect sizes after adjustment. The light grey line indicates the effect size at different standard errors.

Supplementary Figure 15: The upper figure shows the standard p-curve (blue) compared to a null effect (red, dotted) and a true effect at insufficient power (green, dashed) . The lower figure shows the adjusted effect size estimate. The latter is unreliable due to the high heterogeneity, though.

Supplementary tables

Supplementary Table 1

Authors	Year	Reason for exclusion
Dick et al.	2007	Education wasn't a predictor of interest
Torrealba-Acosta et al.	2021	Education wasn't a predictor of interest
Georgiou et al.	2019	Education wasn't a predictor of interest
Marder et al.	1998	Education wasn't a predictor of interest
Nicoletti et al.	2010	Wrong type of study
Belvisi et al.	2020	Education wasn't a predictor of interest
Alcalay et al.	2011	Education wasn't a predictor of interest
Sohn et al.	2016	Wrong publication type

Yang et al.	2014	Investigated SES not education
Zhu et al.	2024	Wrong publication type

Characteristics of the included studies for the secondary outcome

Report	Location	Sample size	effect metric
Blume 2017	Germany	102	UPDRS III
de Oliveira Souza 2013	Brazil	58	H & Y, UPDRS I & III, BBS
Hemming 2011	USA	1,159	UPDRS total, UPDRS III
Jeong 2022	South Korea	478	UPDRS III, LID HR
Kotagal 2015	USA	142	UPDRS III
Martínez-Rumayor 2009	Mexico	247	age at symptom onset
Sunwoo 2016	South Korea	182	UPDRS III
Valenzuela 2022	Spain	40	Gait speed

UPDRS III = Unified Parkinson's Disease Rating Scale motor subscale; H & Y = Hoehn & Yahr stage; BBS = Berg Balance Scale; LID HR = Levodopa-induced dyskinesia hazard ratio;

Risk-of-bias judgment for each of six domains of bias, and for the overall risk of bias of studies on our secondary outcome

report	Study Participation	Study Attrition	Education Measurement	PD Measurement	Confounding	Statistical Analysis and Reporting	Overall RoB
Blume 2017	moderate RoB	moderate RoB	low RoB	low RoB	moderate RoB	low RoB	moderate RoB
de Oliveira Souza 2013	moderate RoB		low RoB	low RoB	high RoB	low RoB	high RoB
Hemming 2011	moderate RoB		moderate RoB	low RoB	moderate RoB	low RoB	moderate RoB
Jeong 2022	moderate RoB	moderate RoB	low RoB	low RoB	low RoB	low RoB	low RoB
Koatagal 2015	moderate RoB		low RoB	low RoB	moderate RoB	moderate RoB	moderate RoB
Martínez-Rumayor 2009	moderate RoB		low RoB	low RoB	low RoB	moderate RoB	moderate RoB
Sunwoo 2016	moderate RoB		low RoB	low RoB	low RoB	low RoB	low RoB
Valenzuela 2022	moderate RoB		low RoB	low RoB	low RoB	high RoB	high RoB

RoB = risk of bias; PD = parkinson's disease
Sunwoo 2016 and Jeong 2022 are based on the same registry.

Results of meta-analyses excluding outliers

Analysis	n studies	OR (95% CI)	t-/z-value	p-value	prediction interval	tau²	I² (%)	Q / Q'-Q	df	p-value of Q
main	22	1.1 (0.98 - 1.24)	1.784	0.089	0.73 - 1.67	0.037	73.4	78.919	21	0.000
subgroup smoking	22	1.1 (0.98 - 1.24)	1.784	0.089	0.73 - 1.67	0.041	72.1	0.001	1	0.973
smoking not controlled	16	1.1 (0.97 - 1.26)	1.607	0.129	0.7 - 1.74	0.041	70.1	50.137	20	0.000
smoking controlled	6	1.1 (0.79 - 1.53)	0.737	0.494	0.61 - 1.98	0.041	76.9	21.602		0.001
subgroup representative	22	1.1 (0.98 - 1.24)	1.784	0.089	0.73 - 1.67	0.036	62.3	1.036	1	0.309
not representative	9	1.02 (0.8 - 1.29)	0.142	0.890	0.62 - 1.66	0.036	54.0	17.378	20	0.026
representative	13	1.15 (1.01 - 1.31)	2.273	0.042	0.74 - 1.78	0.036	66.4	35.707		0.000
subgroup PD assessment	22	1.1 (0.98 - 1.24)	1.784	0.089	0.73 - 1.67	0.037	72.8	0.977	1	0.323
not all assessed	14	1.07 (0.92 - 1.23)	0.956	0.357	0.69 - 1.65	0.037	78.4	60.208	20	0.000
all assessed	8	1.2 (0.95 - 1.5)	1.877	0.103	0.71 - 2	0.037	47.0	13.205		0.067
subgroup income	22	1.1 (0.98 - 1.24)	1.784	0.089	0.73 - 1.67	0.034	71.0	1.483	1	0.223
HIC	8	1.23 (0.94 - 1.62)	1.856	0.106	0.75 - 2.04	0.034	43.6	12.420	20	0.088
L/MIC	14	1.06 (0.93 - 1.2)	0.938	0.365	0.69 - 1.61	0.034	77.0	56.513		0.000
limit meta-analysis	22	1.09 (0.93 - 0.93)	1.054	0.292		0.037	73.4	13.900	1	0.000

OR (95% CI): Odds ratio with 95% confidence interval (adjusted for limit meta-analysis row); t-/z-value: z-value for limit meta-analysis, t-value for all others; p-value: p-value of the effect of education; tau² / I²: measures of heterogeneity for main analysis, measures of residual heterogeneity for overall subgroup analyses, measures of heterogeneity within the subgroup for individual subgroups; Q/Q'-Q/df/p-value of Q = results of test of heterogeneity for main analysis and for individual subgroups, results of test for subgroup differences for overall subgroup analyses, results of test of small-study effects for limit meta-analysis
df = degrees of freedom; HIC = high-income country, L/MIC = low- or middle-income country

Results of meta-analyses excluding studies reporting other effect measures than odds ratios

Analysis	n studies	OR (95% CI)	t-/z-value	p-value	prediction interval	tau²	I² (%)	Q / Q'-Q	df	p-value of Q
main	18	1.1 (0.87 - 1.38)	0.866	0.398	0.46 - 2.61	0.158	76.5	72.332	17	0.000
subgroup smoking	18	1.1 (0.87 - 1.38)	0.866	0.398	0.46 - 2.61	0.152	75.0	1.586	1	0.208
smoking not controlled	12	1 (0.74 - 1.36)	-0.007	0.995	0.4 - 2.47	0.152	72.0	39.321	16	0.000
smoking controlled	6	1.3 (0.87 - 1.94)	1.680	0.154	0.43 - 3.91	0.152	79.8	24.739		0.000
subgroup representative	18	1.1 (0.87 - 1.38)	0.866	0.398	0.46 - 2.61	0.131	76.2	3.141	1	0.076
not representative	9	0.9 (0.6 - 1.36)	-0.579	0.578	0.37 - 2.22	0.131	77.1	34.872	16	0.000
representative	9	1.3 (1.03 - 1.63)	2.618	0.031	0.53 - 3.16	0.131	75.2	32.276		0.000
subgroup PD assessment	18	1.1 (0.87 - 1.38)	0.866	0.398	0.46 - 2.61	0.167	77.9	0.406	1	0.524
not all assessed	11	1.05 (0.73 - 1.5)	0.280	0.785	0.4 - 2.74	0.167	83.5	60.590	16	0.000
all assessed	7	1.19 (0.9 - 1.56)	1.537	0.175	0.4 - 3.54	0.167	48.9	11.734		0.068
subgroup income	18	1.1 (0.87 - 1.38)	0.866	0.398	0.46 - 2.61	0.167	77.5	0.367	1	0.545
HIC	7	1.19 (0.82 - 1.73)	1.148	0.295	0.4 - 3.57	0.167	49.2	11.805	16	0.066
L/MIC	11	1.05 (0.75 - 1.46)	0.308	0.764	0.4 - 2.74	0.167	83.1	59.196		0.000
limit meta-analysis	18	1.13 (0.8 - 0.8)	0.697	0.486		0.158	76.5	0.213	1	0.645

OR (95% CI): Odds ratio with 95% confidence interval (adjusted for limit meta-analysis row); t/z-value: z-value for limit meta-analysis, t-value for all others; p-value: p-value of the effect of education; tau² / I²: measures of heterogeneity for main analysis, measures of residual heterogeneity for overall subgroup analyses, measures of heterogeneity within the subgroup for individual subgroups; Q/Q'-Q/df/p-value of Q = results of test of heterogeneity for main analysis and for individual subgroups, results of test for subgroup differences for overall subgroup analyses, results of test of small-study effects for limit meta-analysis
df = degrees of freedom; HIC = high-income country, L/MIC = low- or middle-income country

Results of meta-analyses excluding mendelian randomization studies

Analysis	n studies	OR (95% CI)	t-/z-value	p-value	prediction interval	tau²	I² (%)	Q / Q'-Q	df	p-value of Q
main	22	1.04 (0.88 - 1.22)	0.497	0.624	0.54 - 2	0.094	74.0	80.870	21	0.000
subgroup smoking	22	1.04 (0.88 - 1.22)	0.497	0.624	0.54 - 2	0.102	75.2	0.005	1	0.943
smoking not controlled	17	1.04 (0.85 - 1.27)	0.440	0.666	0.52 - 2.1	0.102	76.6	68.442	20	0.000
smoking controlled	5	1.03 (0.68 - 1.56)	0.191	0.858	0.38 - 2.8	0.102	67.6	12.363		0.015
subgroup representative	22	1.04 (0.88 - 1.22)	0.497	0.624	0.54 - 2	0.087	67.6	1.656	1	0.198
not representative	10	0.91 (0.65 - 1.29)	-0.584	0.574	0.45 - 1.88	0.087	74.2	34.872	20	0.000
representative	12	1.13 (0.98 - 1.31)	1.886	0.086	0.57 - 2.24	0.087	59.0	26.832		0.005
subgroup PD assessment	22	1.04 (0.88 - 1.22)	0.497	0.624	0.54 - 2	0.087	73.3	2.501	1	0.114
not all assessed	14	0.97 (0.77 - 1.21)	-0.340	0.739	0.5 - 1.88	0.087	78.9	61.596	20	0.000
all assessed	8	1.21 (0.96 - 1.52)	1.942	0.093	0.56 - 2.59	0.087	47.0	13.205		0.067
subgroup income	22	1.04 (0.88 - 1.22)	0.497	0.624	0.54 - 2	0.085	71.5	2.397	1	0.122
HIC	8	1.23 (0.91 - 1.65)	1.633	0.146	0.58 - 2.61	0.085	43.6	12.420	20	0.088
L/MIC	14	0.96 (0.79 - 1.18)	-0.400	0.696	0.5 - 1.86	0.085	77.5	57.732		0.000
limit meta-analysis	22	1.05 (0.84 - 0.84)	0.439	0.661		0.094	74.0	4.059	1	0.044

OR (95% CI): Odds ratio with 95% confidence interval (adjusted for limit meta-analysis row); t-/z-value: z-value for limit meta-analysis, t-value for all others; p-value: p-value of the effect of education; tau² / I²: measures of heterogeneity for main analysis, measures of residual heterogeneity for overall subgroup analyses, measures of heterogeneity within the subgroup for individual subgroups; Q/Q'-Q/df/p-value of Q = results of test of heterogeneity for main analysis and for individual subgroups, results of test for subgroup differences for overall subgroup analyses, results of test of small-study effects for limit meta-analysis

df = degrees of freedom; HIC = high-income country, L/MIC = low- or middle-income country

Supplementary Table 7

Results of meta-analyses excluding studies with a high risk of bias

Analysis	n studies	OR (95% CI)	t-/z-value	p-value	prediction interval	tau²	I² (%)	Q / Q'-Q	df	p-value of Q
main	13	1.05 (0.77 - 1.42)	0.315	0.758	0.38 - 2.9	0.199	78.3	55.422	12	0.000
subgroup smoking	13	1.05 (0.77 - 1.42)	0.315	0.758	0.38 - 2.9	0.224	80.2	0.009	1	0.924
smoking not controlled	8	1.03 (0.62 - 1.73)	0.154	0.882	0.31 - 3.47	0.224	80.6	36.004	11	0.000
smoking controlled	5	1.06 (0.68 - 1.66)	0.369	0.731	0.25 - 4.58	0.224	79.4	19.416		0.001
subgroup representative	13	1.05 (0.77 - 1.42)	0.315	0.758	0.38 - 2.9	0.179	75.5	1.710	1	0.191
not representative	6	0.84 (0.42 - 1.68)	-0.651	0.544	0.25 - 2.81	0.179	80.9	26.216	11	0.000
representative	7	1.23 (0.93 - 1.62)	1.835	0.116	0.4 - 3.78	0.179	67.9	18.686		0.005
subgroup PD assessment	13	1.05 (0.77 - 1.42)	0.315	0.758	0.38 - 2.9	0.192	80.1	1.464	1	0.226
not all assessed	7	0.9 (0.51 - 1.6)	-0.448	0.670	0.28 - 2.9	0.192	86.4	44.034	11	0.000
all assessed	6	1.24 (0.9 - 1.7)	1.748	0.141	0.36 - 4.29	0.192	55.7	11.293		0.046
subgroup income	13	1.05 (0.77 - 1.42)	0.315	0.758	0.38 - 2.9	0.192	78.5	1.406	1	0.236
HIC	5	1.3 (0.71 - 2.36)	1.198	0.297	0.33 - 5.14	0.192	56.5	9.191	11	0.057
L/MIC	8	0.93 (0.61 - 1.42)	-0.413	0.692	0.3 - 2.83	0.192	83.3	41.989		0.000
limit meta-analysis	13	1.02 (0.62 - 0.62)	0.059	0.953		0.199	78.3	3.150	1	0.076

OR (95% CI): Odds ratio with 95% confidence interval (adjusted for limit meta-analysis row); t/z-value: z-value for limit meta-analysis, t-value for all others; p-value: p-value of the effect of education; tau² / I²: measures of heterogeneity for main analysis, measures of residual heterogeneity for overall subgroup analyses, measures of heterogeneity within the subgroup for individual subgroups; Q/Q'-Q/df/p-value of Q = results of test of heterogeneity for main analysis and for individual subgroups, results of test for subgroup differences for overall subgroup analyses, results of test of small-study effects for limit meta-analysis
df = degrees of freedom; HIC = high-income country, L/MIC = low- or middle-income country

Supplementary Table 8

Results of meta-analyses including only one Swedish register-based study

Analysis	n studies	OR (95% CI)	t-/z-value	p-value	prediction interval	tau²	I² (%)	Q / Q'-Q	df	p-value of Q
main	22	1.06 (0.89 - 1.27)	0.724	0.477	0.5 - 2.25	0.121	76.8	90.487	21	0.000
subgroup smoking	22	1.06 (0.89 - 1.27)	0.724	0.477	0.5 - 2.25	0.126	75.4	0.504	1	0.478
smoking not controlled	16	1.02 (0.82 - 1.27)	0.222	0.827	0.47 - 2.25	0.126	71.3	52.351	20	0.000
smoking controlled	6	1.18 (0.75 - 1.85)	0.949	0.386	0.43 - 3.22	0.126	82.8	29.090		0.000
subgroup representative	22	1.06 (0.89 - 1.27)	0.724	0.477	0.5 - 2.25	0.109	72.7	2.216	1	0.137
not representative	10	0.91 (0.64 - 1.3)	-0.594	0.567	0.41 - 2.03	0.109	74.2	34.872	20	0.000
representative	12	1.19 (0.98 - 1.43)	2.007	0.070	0.55 - 2.55	0.109	71.3	38.363		0.000
subgroup PD assessment	22	1.06 (0.89 - 1.27)	0.724	0.477	0.5 - 2.25	0.120	76.3	1.597	1	0.206
not all assessed	14	1 (0.77 - 1.29)	-0.037	0.971	0.46 - 2.18	0.120	81.7	71.033	20	0.000
all assessed	8	1.21 (0.96 - 1.52)	1.963	0.090	0.5 - 2.95	0.120	47.0	13.205		0.067
subgroup income	22	1.06 (0.89 - 1.27)	0.724	0.477	0.5 - 2.25	0.119	74.9	1.471	1	0.225
HIC	8	1.22 (0.9 - 1.66)	1.561	0.163	0.5 - 2.97	0.119	43.6	12.420	20	0.088
L/MIC	14	0.99 (0.78 - 1.26)	-0.048	0.962	0.46 - 2.17	0.119	80.6	67.116		0.000
limit meta-analysis	22	1.07 (0.82 - 0.82)	0.490	0.624		0.121	76.8	6.234	1	0.013

OR (95% CI): Odds ratio with 95% confidence interval (adjusted for limit meta-analysis row); t/z-value: z-value for limit meta-analysis, t-value for all others; p-value: p-value of the effect of education; tau² / I²: measures of heterogeneity for main analysis, measures of residual heterogeneity for overall subgroup analyses, measures of heterogeneity within the subgroup for individual subgroups; Q/Q'-Q/df/p-value of Q = results of test of heterogeneity for main analysis and for individual subgroups, results of test for subgroup differences for overall subgroup analyses, results of test of small-study effects for limit meta-analysis
df = degrees of freedom; HIC = high-income country, L/MIC = low- or middle-income country

Supplementary Table 9

										Results of the p-curve-analysis of the meta-analysis excluding outliers		
n of studies	n p < 0.05	n p < 0.025	Test	p binomial	z full	p full	z half	p half	Power estimate	Evidential value	Effect estimate
22	6	4	right-skewness	0.344	-2.711	0.003	-2.861	0.002	0.59 (0.167 - 0.888)	yes	0.008
22	6	4	flatness	0.549	0.952	0.829	3.055	0.999	0.59 (0.167 - 0.888)	no	0.008

Power estimate: The power estimate and 95% confidence interval; Effect estimate: estimated true effect d; p binomial: p-value of the binomial test comparing significant p-values above and below 0.025; z/p full/half: effect measures and measures of significance of the pp-value based tests of right-skewness/flatness for the full sample (all significant p-values) and half of the sample (only p-values > 0.025)
The test of right-skewness tests for evidential for an actual effect. The test of flatness tests for evidential value of an absence of a real effect.